MDM2 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, clonogenic assays performed by administrating increasing doses of SP‐141 (from .25 to 1.25 μM) suggested that MDM2‐specific inhibition had more significant effects in BC‐CML patients showing low SETD2 levels and activity as compared with BC‐CML patients showing intermediate SETD2 levels and activity.